Dr. Reddy's says diabetes drug meets clinical goals
HYDERABAD, India An India-based drug maker said its investigational drug for treating diabetes met its goals in a phase 3 trial.
Dr. Reddy’s and Denmark-based Rheoscience said that balaglitazone, a diabetes drug, met its primary endpoint of reduction of blood glucose levels in its study of insulin therapy for a period of 26 weeks.
“These results offer the opportunity for a constructive series of dialogues with both potential partners as well as regulatory agencies. We look forward to working with Rheoscience to define the path forward for balaglitazone,” said GV Prasad, vice chairman and CEO, Dr. Reddy’s.